| 1 |
34854834 | Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies. | 2022 Jan 1 |
1 |
| 2 |
35216478 | Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia. | 2022 Feb 21 |
1 |
| 3 |
35368106 | Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis. | 2022 Apr 3 |
1 |
| 4 |
35576022 | Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation. | 2022 May 16 |
1 |
| 5 |
33449813 | Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. | 2021 May 10 |
2 |
| 6 |
33600210 | Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). | 2021 May 10 |
5 |
| 7 |
34070172 | The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. | 2021 May 18 |
1 |
| 8 |
34405020 | The Differential Antitumor Activity of 5-Aza-2'-deoxycytidine in Prostate Cancer DU145, 22RV1, and LNCaP Cells. | 2021 |
2 |
| 9 |
34768330 | Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine. | 2021 Oct 20 |
2 |
| 10 |
31488557 | Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. | 2020 Jun |
4 |
| 11 |
31990086 | Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. | 2020 May |
2 |
| 12 |
32482751 | To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia. | 2020 Jun |
1 |
| 13 |
33001991 | Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. | 2020 |
4 |
| 14 |
30728460 | Derepression of LOXL4 inhibits liver cancer growth by reactivating compromised p53. | 2019 Nov |
3 |
| 15 |
31048321 | Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. | 2019 Jul |
1 |
| 16 |
29648492 | Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation. | 2018 Nov |
1 |
| 17 |
27029827 | Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region. | 2017 |
3 |
| 18 |
28476801 | Azacytidine-induced Chemosensitivity to Doxorubicin in Human Breast Cancer MCF7 Cells. | 2017 May |
2 |
| 19 |
28484169 | Current diagnosis and treatment for myelodysplastc syndromes. | 2017 |
1 |
| 20 |
28505595 | Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. | 2017 Jul |
4 |
| 21 |
28802167 | Induction of senescence in cancer cells by 5'-Aza-2'-deoxycytidine: Bioinformatics and experimental insights to its targets. | 2017 Oct |
1 |
| 22 |
28916527 | Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer. | 2017 Dec 1 |
2 |
| 23 |
29143344 | Down-regulation of p16 and MGMT promotes the anti-proliferative and pro-apoptotic effects of 5-Aza-dC and radiation on cervical cancer cells. | 2017 Dec |
1 |
| 24 |
26651421 | A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics. | 2016 Feb |
3 |
| 25 |
25934763 | Correction to "5-aza-Cytidine Is a Potent Inhibitor of DNA Methyltransferase 3a and Induces Apoptosis in HCT-116 Colon Cancer Cells via Gadd45- and p53-Dependent Mechanisms". | 2015 Jun |
1 |
| 26 |
24836762 | Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. | 2014 Jul |
4 |
| 27 |
25134538 | TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells. | 2014 Aug |
2 |
| 28 |
23924947 | Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells. | 2013 Oct |
2 |
| 29 |
24319226 | Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. | 2013 |
2 |
| 30 |
22893484 | Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. | 2012 Dec |
1 |
| 31 |
23300844 | Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. | 2012 |
5 |
| 32 |
21903246 | The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study. | 2011 Nov |
3 |
| 33 |
19531575 | Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. | 2009 Jul |
5 |
| 34 |
15547111 | 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. | 2005 Feb |
4 |
| 35 |
16007224 | Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: implications for pathogenesis and therapeutic approach. | 2005 Sep 1 |
1 |
| 36 |
8790940 | Selective expression of mutated p53 in human cells immortalized with either 4-nitroquinoline 1-oxide or 60Co gamma rays. | 1996 Apr |
2 |